# US 10,946,002 B2 · Pharmaceutical suspension dosage form of benzimidazole compounds and process of preparation thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,946,002 B2
- Document ID: US10946002B2
- Status: Granted
- Kind: B2
- Application number: 16/087,039
- Filed: 2017-10-06
- Published: 2019-07-18
- Granted: 2021-03-16
- Earliest claimed: 2016-10-06
- Assignees: Jubilant Generics Limited
- Applicants: Jubilant Generics Limited
- Inventors: Kamal Surendrakumar Mehta; Dinesh Kumar; Saurabh Srivastava; Basudev Paul
- Web page: https://patentgrep.com/patent/US10946002B2

## CPC

- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K 9/5078: {with drug-free core}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a solid oral pharmaceutical dosage form suitable for making a suspension comprising acid labile benzimidazole compounds and process for preparing the same. The prior art discloses various technical challenges associated with the granules for reconstitution into suspension like agglomeration of particles, viscosity and gelling time. The solid oral pharmaceutical dosage form of the present invention forms a homogeneous suspension upon admixing with an aqueous medium and exhibits desired technical attributes like viscosity, drug release, gelling time, dissolution and reduced adherence to nasogastric and gastric tubes.

## Claims

### Claim 1

A solid oral dosage form consisting of enteric coated pellets of esomeprazole magnesium and a suspension modifying inactive granulate, wherein:
the enteric coated pellets of esomeprazole magnesium consist of:
18.78% (w/w) of sugar spheres;
a first layer on the spheres and consisting of 25.11% (w/w) esomeprazole magnesium, 1.7% (w/w) hydroxypropylmethyl cellulose and 0.5% (w/w) polysorbate 80;
a second layer on the spheres positioned over the first layer and consisting of 9.03% (w/w) hydroxypropyl cellulose, 1.23% (w/w) magnesium stearate and 17.08% (w/w) talc; and
a third layer on the spheres positioned over the second layer and consisting of 23.74% (w/w) methacrylic acid copolymer, 1.23% (w/w) glycerol monostearate, 0.13% (w/w) polysorbate 80 and 1.47% (w/w) triethyl citrate over the second layer, wherein the weight percentages are of the enteric coated pellets; and
the suspension modifying inactive granulate consists of 95.11% (w/w) of lactose/mannitol/dextrose, 2.38% (w/w) of carrageenan, 2.38% (w/w) of crospovidone, 0.08% (w/w) of citric acid and 0.05% (w/w) of iron oxide.

### Claim 2 (depends on 1)

The solid oral dosage form of claim 1, wherein the solid oral dosage form exhibits a dissolution profile comparable to the marketed esomeprazole delayed release granules for suspension wherein 0-5% of the esomeprazole is released in 0.1N HCl (300 ml) for 2 hours and at least 80% of the esomeprazole is released in phosphate buffer (pH 6.8; 1000 ml) using a USP II apparatus at 100 rpm for 30 minutes.

### Claim 3 (depends on 1)

The solid oral dosage form of claim 1, wherein the suspension modifying inactive granulate is free of a binder.

### Claim 4 (depends on 1)

The solid oral dosage form of claim 1, wherein the carrageenan of the inactive granulate is a gelling agent.

### Claim 5 (depends on 4)

The solid oral dosage form of claim 4, wherein the carrageenan is within the granulate.

### Claim 6 (depends on 1)

The solid oral dosage form of claim 1, wherein the gelling time of the dosage form is less than five minutes.

### Claim 7 (depends on 1)

The solid oral dosage form of claim 1, wherein the gelling time of the dosage form is less than four minutes.

### Claim 8 (depends on 1)

The solid oral dosage form of claim 1, wherein the dosage form is a free flowing mixture of the pellets and the granulate.

### Claim 9 (depends on 1)

The solid oral dosage form of claim 1, wherein the pellets of esomeprazole magnesium are made in a process comprising the steps of:
(a) mixing the hydroxypropylmethyl cellulose and the polysorbate 80 with water;
(b) adding the esomeprazole magnesium to the mixture of step (a);
(c) coating the sugar spheres with the mixture of step (b);
(d) mixing the hydroxypropyl cellulose with water;
(e) mixing the talc and the magnesium stearate with water;
(f) adding the mixture of step (e) to the mixture of step (d) and mixing;
(g) applying the mixture of step (f) to the coated sugar spheres of step (c);
(h) adding the glycerol monostearate to water and mixing;
(i) adding the polysorbate 80 and the triethyl citrate to the mixture of step (h) and stirring;
(j) adding the methacrylic acid copolymer to the mixture of step (i); and
(k) coating the mixture of step (j) to the coated sugar spheres of step (g).

### Claim 10 (depends on 1)

The solid oral dosage form of claim 1, wherein the suspension modifying inactive granulate is made in a process comprising the steps of:
(a) mixing the lactose/mannitol/dextrose, carrageenan, crospovidone, citric acid and iron oxide; and
(b) granulating the mixture of step (a) with a solvent to form the granulate.

### Claim 11

A solid oral dosage form consisting of enteric coated pellets of esomeprazole magnesium and a suspension modifying inactive granulate, wherein:
the enteric coated pellets of esomeprazole magnesium consist of:
18.78% (w/w) of sugar spheres coated with a first layer, a second layer and an outermost third layer, and the first layer consists of 25.11% (w/w) esomeprazole magnesium, 1.7% (w/w) hydroxypropylmethyl cellulose and 0.5% (w/w) polysorbate 80;
the second layer consists of 9.03% (w/w) hydroxypropyl cellulose, 1.23% (w/w) magnesium stearate and 17.08% (w/w) talc over the first layer;
and the third outermost layer consists of 23.74% (w/w) methacrylic acid copolymer, 1.23% (w/w) glycerol monostearate, 0.13% (w/w) polysorbate 80 and 1.47% (w/w) triethyl citrate over the second layer, wherein the weight percentages are of the enteric coated pellets; and
the suspension modifying inactive granulate consists of 94.87% (w/w) dextrose, 2.5% (w/w) xanthan gum, 2.5% (w/w) crospovidone, 0.08% (w/w) citric acid and 0.05% (w/w) iron oxide, wherein the weight percentages are of the granulate.

### Claim 12 (depends on 11)

The solid oral dosage form of claim 11, wherein the solid oral dosage form exhibits a dissolution profile comparable to the marketed esomeprazole delayed release granules for suspension wherein 0-5% of the esomeprazole is released in 0.1N HCl (300 ml) for 2 hours and at least 80% of the esomeprazole is released in phosphate buffer (pH 6.8; 1000 ml) using a USP II apparatus at 100 rpm for 30 minutes.

### Claim 13 (depends on 11)

The solid oral dosage form of claim 11, wherein the suspension modifying inactive granulate is free of a binder.

### Claim 14 (depends on 11)

The solid oral dosage form of claim 11, wherein the xanthan gum of the inactive granulate is a gelling agent.

### Claim 15 (depends on 14)

The solid oral dosage form of claim 14, wherein the xanthan gum is within the granulate.

### Claim 16 (depends on 11)

The solid oral dosage form of claim 11, wherein the gelling time of the dosage form is less than five minutes.

### Claim 17 (depends on 11)

The solid oral dosage form of claim 11, wherein the gelling time of the dosage form is less than four minutes.

### Claim 18 (depends on 11)

The solid oral dosage form of claim 11, wherein the dosage form is a free flowing mixture of the pellets and the granulate.

### Claim 19 (depends on 11)

The solid oral dosage form of claim 11, wherein the pellets of esomeprazole magnesium are made in a process comprising the steps of:
(a) mixing the hydroxypropylmethyl cellulose and the polysorbate 80 with water;
(b) adding the esomeprazole magnesium to the mixture of step (a);
(c) coating the sugar spheres with the mixture of step (b);
(d) mixing the hydroxypropyl cellulose with water;
(e) mixing the talc and the magnesium stearate with water;
(f) adding the mixture of step (e) to the mixture of step (d) and mixing;
(g) applying the mixture of step (f) to the coated sugar spheres of step (c);
(h) adding the glycerol monostearate to water and mixing;
(i) adding the polysorbate 80 and the triethyl citrate to the mixture of step (h) and stirring;
(j) adding the methacrylic acid copolymer to the mixture of step (i); and
(k) coating the mixture of step (j) to the coated sugar spheres of step (g).

### Claim 20 (depends on 11)

The solid oral dosage form of claim 11, wherein the suspension modifying inactive granulate is made in a process comprising the steps of:
(a) mixing the dextrose, xanthan gum, crospovidone, citric acid and iron oxide; and
(b) granulating the mixture of step (a) with a solvent to form the granulate.